| Overview |
| bs-1699R-FITC |
| Galectin 9 Polyclonal Antibody, FITC Conjugated |
| WB, FCM, IF(IHC-F) |
| Human, Mouse |
| Rat, Cow, Pig |
| Specifications |
| FITC |
| Rabbit |
| KLH conjugated synthetic peptide derived from mouse Galectin |
| 51-150/353 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 3965 |
| Cytoplasm, Secreted |
| Ecalectin; galectin9; HOM HD 21; HOMHD21; HUAT; Lectin galactoside binding soluble 9; LGAL S9; LGALS 9; LGALS9; LGALS9A; MGC117375; MGC125973; MGC125974 ; Urate transporter/channel protein; Galectin-9; Gal-9. |
| The galectins are a family of beta-galactoside-binding proteins implicated in modulating cell-cell and cell-matrix interactions. Galectin 9 is an S-type lectin and an eosinophil chemoattractant (ECA) produced by antigen-activated T cells. Galectin 9 is involved in apoptosis, is thought to be a prognostic factor for breast cancer and is also overexpressed in Hodgkin's disease tissue. The protein has N- and C- terminal carbohydrate-binding domains connected by a link peptide. Multiple alternatively spliced transcript variants have been found for this gene. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
| IF(IHC-F) |
1:50-200 |
Powered by Bioz